Information Provided By:
Fly News Breaks for November 18, 2019
RCKT
Nov 18, 2019 | 05:47 EDT
After hosting an investor lunch with management, Piper Jaffray analyst Tyler Van Buren says Rocket Pharmaceuticals could "soon take the spot as the next leading lentiviral vector company." By year-end, the analyst expects early clinical observations from the two Process B Fanconi anemia patients and the one LAD-1 patient to give insight into the likely approvability of these programs. The Fanconi anemia update doesn't just de-risk an addressable opportunity that is approaching $1B, it validates Rocket's broader lentiviral gene therapy platform, Van Buren tells investors in a research note. He keeps an Overweight rating on the shares with a $35 price target.